Jeena Sikho Lifecare Ltd
JSLL NSE
Jeena Sikho Lifecare Ltd
HealthcareNSE: JSLL BSE: 544476 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹6,411 Cr
Volatility
Moderate
P/E Ratio
26.77
EBITDA
₹349 Cr
Return on Equity
26.65%
Debt to Equity
0.27
Book Value
₹37.58
52W High
₹849.5
52W Low
₹492
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Jeena Sikho Lifecare Ltd insights
37 extracted metrics + investor summaries across FY19–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
5- Company is expected to give good quarter
- Company has delivered good profit growth of 84.5% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 49.6%
- Company has been maintaining a healthy dividend payout of 19.1%
- Debtor days have improved from 51.4 to 31.8 days.
Weaknesses
1- Stock is trading at 13.8 times its book value
Growth Rate
Revenue Growth
286.57% ↗
Net Income Growth
548.00% ↗
Cash Flow Change
-11.19% ↘
ROE
-13.14% ↘
ROCE
-17.44% ↘
EBITDA Margin (Avg.)
85.59% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 42d agoAI opinion · based on fundamentals
Risk high
Jeena Sikho Lifecare Ltd is a Rs 7,181 Cr market cap company that has delivered exceptional profit growth of 85% CAGR over 5 years and TTM sales growth of 71%, while trading at a P/B of 15.3x and P/E of 32.3x. The company maintains a 3-year average ROE of approximately 50%, indicating high capital efficiency, though its premium valuation leaves limited margin of safety.
Bull Case 8
- Compounded profit growth of 85% CAGR over 5 years demonstrates sustained earnings momentum far exceeding sector averages
- TTM sales growth of 71% indicates strong revenue acceleration and expanding market reach
- 3-year ROE of 50% and last year ROE of 60% reflect exceptional capital efficiency and profitability
- Debtor days improved from 51.4 to 31.8 days, signaling better working capital management and faster cash conversion
- 3-year compounded sales CAGR of 58% shows consistent top-line scaling over a meaningful period
- Healthy dividend payout ratio of 19.1% with 0.19% yield shows willingness to return capital to shareholders even during high-growth phase
- TTM profit growth of 152% suggests a significant step-up in earnings trajectory in the most recent period
- Stock CAGR of 116% over 3 years reflects market recognition of the company's growth execution
Bear Case 8
- P/B ratio of 15.3x is extremely elevated, pricing in substantial future growth and leaving little room for disappointment
- P/E of 32.3x is a premium multiple that requires continued high earnings growth to justify current valuation
- No 52-week high/low data available (reported as 0), limiting ability to assess recent price volatility and technical support levels
- Absence of reported debt-to-equity ratio creates uncertainty around the company's leverage and financial risk profile
- Limited long-term track record with no 10-year sales or profit CAGR data available, making it difficult to assess durability through full market cycles
- Dividend yield of only 0.19% provides negligible income cushion for investors if growth decelerates
- At Rs 7,181 Cr market cap with 85% profit CAGR, sustaining such growth rates becomes mathematically harder as the base expands, creating mean-reversion risk
- Consumer discretionary sector classification exposes the company to demand cyclicality and discretionary spending slowdowns during economic downturns
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 42d ago Positives 4
- Research institute MoU signed Jun 15
JSLL signed a five-year MoU to establish a research institute in Chandigarh focused on Ayurveda and integrative healthcare, strengthening R&D capabilities.
- New 160+ bed Lucknow hospital Jun 12
Proposed 160+ bed hospital in Lucknow spanning ~1.25 lakh sq. ft. with operations commencing August 2026, funded internally at ~₹3 Cr investment.
- 100-bed Mathura hospital operational Jun 10
Sanskriti Ayurvedic P.G. Medical College & Hospital commenced operations on June 10 with 100 beds across 60,000 sq. ft. and OPD capacity of 8.
- Ayodhya day care clinic planned Jun 11
New Day Care Clinic in Ayodhya to be operational by August 2026 with ₹50 Lakh investment, expanding UP footprint.
Neutral 3
- Land sale with lease-back ₹9.05 Cr Jun 19
Board approved sale of Punjab land and building to VSB Enterprises for ₹9.05 Cr; operations continue via lease-back arrangement.
- GIA conference participation Jun 23 Jun 17
Management to attend GIA Flagship Conference on June 23, 2026 in Mumbai for a physical group meeting with analysts.
- Virtual investor meet Jun 12 Jun 9
Investor/analyst meet held on June 12, 2026, organized virtually by Choice Institutional Equities.
TL;DR: JSLL is in aggressive expansion mode, opening new hospitals and clinics across UP (Mathura, Lucknow, Ayodhya) while investing in Ayurveda research via a Chandigarh institute. No material headwinds are visible; the ₹9.05 Cr asset sale with lease-back provides liquidity without disrupting operations. The expansion trend is clearly accelerating with multiple facilities targeting August 2026 commencement, though investors should monitor execution risk across simultaneous projects.
Quarterly Results
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 100 | 114 | 116 | 139 | 174 | 190 | 222 | 216 | 224 |
| Expenses | 75 | 74 | 86 | 93 | 96 | 98 | 121 | 138 | 132 |
| Operating Profit | 25 | 40 | 30 | 46 | 79 | 92 | 101 | 78 | 92 |
| OPM % | 25% | 35% | 26% | 33% | 45% | 48% | 45% | 36% | 41% |
| Other Income | 3 | 3 | 0 | 0 | 1 | 1 | 3 | 4 | 14 |
| Interest | 1 | 2 | 4 | 3 | 2 | 4 | 3 | 4 | 3 |
| Depreciation | 5 | 6 | 8 | 9 | 10 | 10 | 11 | 16 | 15 |
| PBT | 21 | 35 | 18 | 34 | 69 | 79 | 89 | 62 | 87 |
| Tax % | 23% | 25% | 26% | 25% | 25% | 25% | 25% | 26% | 25% |
| Net Profit | 16 | 27 | 13 | 25 | 51 | 59 | 67 | 45 | 66 |
| EPS in Rs | 1.3 | 2.14 | 1.06 | 2.04 | 4.13 | 4.73 | 5.37 | 3.65 | 5.28 |
Profit & Loss
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 106 | 94 | 136 | 146 | 204 | 324 | 469 | 801 | 851 |
| Expenses | 95 | 84 | 119 | 128 | 158 | 231 | 344 | 452 | 488 |
| Operating Profit | 11 | 11 | 17 | 18 | 46 | 93 | 125 | 350 | 363 |
| OPM % | 10% | 11% | 13% | 12% | 23% | 29% | 27% | 44% | 43% |
| Other Income | 0 | 1 | 1 | 1 | 2 | 6 | 6 | 9 | 22 |
| Interest | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 13 | 15 |
| Depreciation | 1 | 2 | 2 | 3 | 3 | 5 | 9 | 48 | 53 |
| PBT | 8 | 8 | 14 | 15 | 45 | 94 | 122 | 298 | 317 |
| Tax % | 28% | 26% | 27% | 26% | 24% | 26% | 26% | 25% | — |
| Net Profit | 6 | 6 | 10 | 11 | 34 | 69 | 91 | 222 | 237 |
| EPS in Rs | 66.67 | 63.67 | 93.55 | 1.24 | 2.71 | 5.57 | 7.3 | 17.87 | 19.03 |
| Div. Payout % | 0% | 0% | 0% | 0% | 8% | 17% | 15% | 25% | — |
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.1 | 0.1 | 0.1 | 10 | 14 | 25 | 25 | 25 |
| Reserves | 8 | 14 | 24 | 26 | 112 | 167 | 248 | 443 |
| Borrowings | 16 | 12 | 12 | 7 | 1 | 1 | 11 | 127 |
| Other Liabilities | 12 | 12 | 13 | 18 | 24 | 28 | 45 | 78 |
| Total Liabilities | 36 | 38 | 49 | 62 | 151 | 221 | 328 | 673 |
| Fixed Assets | 13 | 17 | 23 | 28 | 60 | 67 | 153 | 307 |
| CWIP | 0 | 0 | 0 | 5 | 1 | 4 | 13 | 2 |
| Investments | 0 | 0 | 0 | 0 | 5 | 4 | 4 | 95 |
| Other Assets | 23 | 21 | 26 | 28 | 86 | 146 | 159 | 269 |
| Total Assets | 36 | 38 | 49 | 62 | 151 | 221 | 328 | 673 |
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating | 1 | 12 | 18 | 17 | 17 | 37 | 69 | 262 |
| Investing | -11 | -6 | -8 | -20 | -57 | -18 | -70 | -211 |
| Financing | 7 | -5 | -2 | -5 | 48 | -3 | -1 | -59 |
| Net Cash Flow | -2 | 1 | 8 | -7 | 8 | 15 | -2 | -8 |
| Free Cash Flow | -10 | 6 | 9 | -1 | -13 | 23 | -40 | 231 |
| CFO/OP | 35 | 130 | 125 | 118 | 55 | 66 | 81 | 96 |
Ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 15 | 17 | 9 | 22 | 40 | 46 | 76 | 32 |
| Inventory Days | 204 | 315 | 208 | 136 | 87 | 121 | 135 | 80 |
| Days Payable | 125 | 168 | 73 | 109 | 129 | 75 | 111 | 86 |
| Cash Conversion Cycle | 94 | 163 | 143 | 49 | -2 | 92 | 100 | 26 |
| Working Capital Days | -16 | -15 | -19 | -11 | 29 | 58 | 55 | 54 |
| ROCE % | — | 38% | 50% | 39% | 53% | 58% | 50% | 71% |
Documents
1
Jeena Sikho Lifecare Limited Has informed About Publication Of Case Study And Case Reports.
4 May - Seven case studies and two case reports published in JASE on Ayurvedic treatments. 4 May - Seven case studies and two case reports published in JASE on Ayurvedic treatments.
2
Intimation For Appointment Of Investor Relations Management Agency Of The Company
4 May - Jeena Sikho Lifecare appoints GoIndia Advisors LLP as investor relations management agency. 4 May - Jeena Sikho Lifecare appoints GoIndia Advisors LLP as investor relations management agency.
3
Revised Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015, As Amended ('SEBI Listing
Regulations') - Sale Of Land
2d - Jeena Sikho Lifecare approved sale of 48 bigha non-operational land in Patiala for ₹24 crore. 2d - Jeena Sikho Lifecare approved sale of 48 bigha non-operational land in Patiala for ₹24 crore.
4
Sale Of Land - Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
8 May - Board approved sale of 48 bigha land in Punjab for ₹24 crore on 8 May 2026. 8 May - Board approved sale of 48 bigha land in Punjab for ₹24 crore on 8 May 2026.
5
Jeena Sikho Lifecare Limited Has informed About Publication Of Case Study And Case Reports.
4 May - Seven case studies and two case reports published in JASE on Ayurvedic treatments. 4 May - Seven case studies and two case reports published in JASE on Ayurvedic treatments.
Frequently Asked Questions about Jeena Sikho Lifecare Ltd
What does Jeena Sikho Lifecare Ltd do?
Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.
Where is Jeena Sikho Lifecare Ltd (JSLL) listed?
Jeena Sikho Lifecare Ltd is listed on the Indian stock exchanges. It is listed on NSE: JSLL and BSE: 544476. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Jeena Sikho Lifecare Ltd belong to?
Jeena Sikho Lifecare Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Jeena Sikho Lifecare Ltd?
Jeena Sikho Lifecare Ltd has a market capitalisation of approximately ₹6410.81 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Jeena Sikho Lifecare Ltd?
The Price-to-Earnings (PE) ratio of Jeena Sikho Lifecare Ltd is 26.77. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Jeena Sikho Lifecare Ltd?
Over the past 52 weeks, Jeena Sikho Lifecare Ltd has traded between a low of ₹492 and a high of ₹849.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Jeena Sikho Lifecare Ltd pay dividends?
Yes, Jeena Sikho Lifecare Ltd has a dividend yield of 0.21%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Jeena Sikho Lifecare Ltd?
Jeena Sikho Lifecare Ltd has a Return on Equity (ROE) of 26.65%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Jeena Sikho Lifecare Ltd on Tapetide?
On Tapetide, you can view Jeena Sikho Lifecare Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.